Vir Biotechnology layoffs, on the record
Every job cut, severance charge and restructuring Vir Biotechnology reported in its annual reports, 2023 to 2025, quoted from the filings.
Job cuts, severance and restructuring
Our summaryIn December 2023 the company started strategic steps to cut operating expenses and focus capital on its highest-potential programs under a Restructuring Plan.
Word for word“In December 2023, the Company initiated strategic steps to reduce operating expenses and focus its capital allocation on programs with the highest potential for patient impact and value creation (“Restructuring Plan”).” 10-K for 2023
Our summaryThe company plans to eliminate about 75 net positions, including reductions from discontinuing its innate immunity small molecule group, which began in the third quarter of 2023.
Word for word“In addition, approximately 75 net positions, or 12 % of the workforce, will be eliminated, which includes reductions from the Company’s discontinuation of its innate immunity small molecule group that was initiated in the third quarter of 2023.” 10-K for 2023
Our summaryThe company recorded severance and other employee-related expenses tied to the Restructuring Plan during 2023, split between R&D and SG&A.
Word for word“During the year ended December 31, 2023, the Company incurred severance and other employee-related expenses of $ 5.9 million, of which $ 4.0 million is included in research and development expense and $ 1.9 million is included in selling, general and administrative expense.” 10-K for 2023
Our summaryThe company expects additional restructuring charges, primarily for facility closures, and had $4.5 million of restructuring liabilities accrued at year end.
Word for word“As of December 31, 2023, the Company recorded $ 4.5 million as accrued and other liabilities related to restructuring costs.” 10-K for 2023
Our summaryResearch and development personnel expenses rose in 2023 partly due to severance and other personnel costs from strategic steps to reduce operating expenses adopted in 2023.
Word for word“the increase in personnel-related expenses was primarily attributable to supporting the advancement of our clinical programs and severance and other personnel related costs incurred in connection with strategic steps to reduce operating expenses adopted in 2023; and” 10-K for 2023
Our summaryThe company started a cost-cutting restructuring plan in December 2023 to reduce operating expenses and focus capital on its highest-potential programs.
Word for word“In December 2023, the Company initiated strategic steps to reduce operating expenses and focus its capital allocation on programs with the highest potential for patient impact and value creation (“2023 Restructuring Plan”).” 10-K for 2024
Our summaryThe company started a strategic restructuring to advance its hepatitis programs, focusing on the highest near-term value opportunities.
Word for word“In August 2024, the Company initiated a strategic restructuring to advance the development of its hepatitis programs and focus on the highest near-term value opportunities (“2024 Restructuring Plan”).” 10-K for 2024
Our summaryThe 2024 plan phased out influenza, COVID-19 and T cell-based viral vector programs and reduced the workforce by about 25%, or about 140 employees.
Word for word“The organizational realignment and optimization included phasing out programs in influenza, COVID-19, and the Company’s T cell-based viral vector platform, as well as a workforce reduction of approximately 25 % or approximately 140 employees.” 10-K for 2024
Our summaryIn August 2024 the company began a restructuring to focus on its hepatitis programs, phasing out other programs and cutting about a quarter of its workforce.
Word for word“In August 2024, the Company initiated a strategic restructuring to advance the development of its hepatitis programs and focus on the highest near-term value opportunities (2024 Restructuring Plan).” 10-K for 2025
| Fiscal year ended | Severance costs | Restructuring charges | Cash paid for restructuring |
|---|---|---|---|
| 2023-12-31 | $5.9 million | $13.6 million | $1.4 million |
| 2024-12-31 | — | $35 million | $13.7 million |
Vir Biotechnology filed 2 restructuring notices (Form 8-K, Item 2.05) since 2016. This page shows what the company reported to the SEC, not news reports or state layoff notices.
Read from Vir Biotechnology’s annual reports (10-K for 2025, 10-K for 2024, 10-K for 2023) and the financial data it files with the SEC, as of 2026-02-23. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.